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Abstract
Introduction: Wnt signalling has been implicated in stem cell regulation however its role in breast cancer stem cell
regulation remains unclear.
Methods: We used a panel of normal and breast cancer cell lines to assess Wnt pathway gene and protein expression, and
for the investigation of Wnt signalling within stem cell-enriched populations, mRNA and protein expression was analysed
after the selection of anoikis-resistant cells. Finally, cell lines and patient-derived samples were used to investigate Wnt
pathway effects on stem cell activity in vitro.
Results: Wnt pathway signalling increased in cancer compared to normal breast and in both cell lines and patient samples,
expression of Wnt pathway genes correlated with estrogen receptor (ER) expression. Furthermore, specific Wnt pathway
genes were predictive for recurrence within subtypes of breast cancer. Canonical Wnt pathway genes were increased in
breast cancer stem cell-enriched populations in comparison to normal breast stem cell-enriched populations. Furthermore
in cell lines, the ligand Wnt3a increased whilst the inhibitor DKK1 reduced mammosphere formation with the greatest
inhibitory effects observed in ER+ve breast cancer cell lines. In patient-derived metastatic breast cancer samples, only ER-ve
mammospheres were responsive to the ligand Wnt3a. However, the inhibitor DKK1 efficiently inhibited both ER+ve and ER-
ve breast cancer but not normal mammosphere formation, suggesting that the Wnt pathway is aberrantly activated in
breast cancer mammospheres.
Conclusions: Collectively, these data highlight differential Wnt signalling in breast cancer subtypes and activity in patient-
derived metastatic cancer stem-like cells indicating a potential for Wnt-targeted treatment in breast cancers.
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Introduction
WNT proteins are a family of secreted, glycosylated, and
palmitoylated peptides which function in diverse processes such as
embryonic induction, generation of cell polarity, and cell fate
specification [1]. Aberrant activation of Wnt signaling has been
described in a number of human cancers including colorectal
cancer, ovarian cancer and breast cancer [2,3,4,5,6,7]. b-catenin
expression has been associated with poor prognosis in breast
cancer patients in a number of studies [8,9] and is enriched in
basal-like breast cancer [6]. Furthermore loss of negative pathway
regulators such as the extracellular inhibitor of WNT signaling,
secreted Frizzled-related protein 1 (sFRP1), is found in many
breast tumors and is associated with poor prognosis [3,10]. Down
regulation of the inhibitor Dickkopf 1 (DKK1) in a lung metastases
derived MCF7-LM cell line demonstrates the importance of Wnt
regulation in the metastatic process in breast cancer [11].
Collectively these data suggest that WNT pathway de-regulation
within the breast contributes to cancer formation and metastasis.
Recent studies suggest breast cancer initiation and recurrence
may be regulated by a small population of cells within the tumor,
either stem cells or cells that exhibit stem-like properties [12].
Transplantation experiments using immunocomprimised mice,
showed that as few as 100 human breast cancer cells with the cell
surface markers CD44+CD242/low were tumorigenic and could be
serially passaged to generate new tumours [13].
Cells isolated from human breast cancers marked by
CD44+CD242/low lineage are anoikis-resistant and capable of
self-renewal as mammosphere (MS) colonies providing a link
between MS and cell surface markers that enrich for tumorgenic
cells [14,15].
Expression of Wnt1 in human mammary epithelial cells
increases stem cell self renewal, resistance to apoptosis and failure
to senesce [16]. More recent work using the MMTV-WNT-1
mouse model has identified an expanded mammary stem cell (SC)
pool from a population of committed luminal progenitors
indicating that Wnt-1 activation induces the appearance of
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aberrant progenitor cells, and suggest that both mammary stem
and progenitor cells can serve as the cellular targets of WNT-1-
induced tumorigenesis [17].
WNT pathway activation increases radio resistance of progen-
itor cells in the mouse mammary gland and human breast cancer
cell lines [18,19], which implicates the WNT pathway in resistance
to current anti-cancer therapies, potentially through the regulation
of stem and progenitor cell populations.
In this study we investigated the WNT pathway both in whole
cell populations and stem-like cells of breast cell lines and patient-
derived metastatic breast cancer samples. WNT pathway gene
expression correlates with estrogen receptor (ER) expression and
molecular sub-type, and some genes predict prognosis. WNT
signalling was found to be activated in breast cancer stem-like cells
compared to normal stem-like cells. Finally, we show that WNT
pathway inhibition preferentially reduces stem-like cell activity in
patient-derived metastatic breast cancer compared to normal cells.
Collectively, these data suggest potential of the WNT-targeted
therapeutics in breast cancer.
Methods
Cell Lines
Six normal breast (HB4A, MRSV4.4, MRSV1.7, MCF10A,
MCF10F, 226L-U19), six ER+ve breast cancer (BT474, MCF7,
MCF7-HER2-18, MDA-MB361, T47D and ZR75-1) and five
ER-ve cancer (BT20, Hs578T, MDA-MB231, MDA-MB468 and
SKBR3) cell lines were used in this study.
Primary Normal Human Breast Cells
Histologically confirmed normal breast tissue was obtained from
3 premenopausal patients undergoing fibroadenoma excision or
breast reduction surgery (n = 3; mean age 38). Normal breast tissue
was prepared and purified as previously described [20]. Briefly,
tissue samples were dissected into 3- to 5-mm cubes and digested
for 16–18 hours at 37uC in serum-free Dulbecco’s modified Eagle
Medium (DMEM; Gibco) containing 200 U/mL type 3 collage-
nase (Worthington Biochemical Corporation), 5 mg/ml pronase
(Roche) and 10x antibiotic/antimycotic (Invitrogen). The cells
were then washed, collected by centrifugation at 1000 g and
filtered to obtain a single-cell suspension, which was verified
microscopically. CD45 positive cells were removed using anti-
CD45 magnetic beads (Miltenyi). CD45 negative cells were then
collected and resuspended in mammosphere culture medium.
Patient-derived Metastatic Breast Cancer Cells
Samples were collected from patients (ER+ve n= 3 and ER-ve
n= 3) with metastatic breast cancer (Table 1). Tumour samples
were prepared and purified as previously described [15]. Briefly,
metastatic fluid was collected and centrifuged at 2000 g from 5
minutes and responded in PBS. Blood cells were removed by
centrifugation through Lymphoprep solution (Axis Shield),
followed by removal of CD45 positive cells using anti-CD45
magnetic beads (Miltenyi). CD45 negative cells were then collected
and resuspended in mammosphere culture medium.
Ethics Statement
Any experimental research reported in the manuscript has been
performed with the approval of an appropriate ethics committee
and in compliance with the Helsinki Declaration. All samples were
collected with informed written consent. Normal breast tissue was
collected with approval from South Manchester Research Ethics
Committee (COREC#05/1403/159). Patient derived metastatic
breast cancer cells were collected with approval from Tameside
and Glossop Local Research Ethics Committee (COREC # 05/
Q1402/25).
Mammosphere Culture
A single cell suspension was created from cell lines grown in
monolayer culture using enzymatic digestion (Trypsin EDTA)
followed by manual disaggregation (25 Gauge needle). Patient-
derived breast cells did not require the addition of trypsin, a single
cell suspension was created using manual disaggregation alone.
Single cells from cell lines and patient derived cells were plated at a
density of 500 cells/cm2 in non-adherent conditions, in culture
flasks coated with (2-hydroxyethylmethacrylate) (poly-HEMA
[Sigma]). Culture of cells in these conditions allows the survival
of stem-like cells and subsequent spheroid growth from a single cell
using both cell lines and primary tissue samples. Mammospheres
grow at a similar rate when plated as single cells or at higher
densities indicating that mammospheres are truly clonal structures
and not formed through aggregation [21,22].
Anoikis resistant cells. were collected after 12 hrs (RNA) or
24 hrs (protein) in non-adherent, mammosphere culture. As
described above, single cell suspensions were obtained and
cultured in non-adherent conditions at a density of 500 cells/
cm2. Anoikis resistant cells were then collected by centrifugation at
1800 rpm for 2 minutes. Prior to RNA/protein extraction cells
were incubated with 100 ul of Dead cell Removal micro-beads
and dead cells removed using an MS column and MACS
Seperator (Miltenyi Biotech). Mammospheres (MS) were
counted after culture for 7 days in MS medium (DMEM: F12
medium supplemented with B27 without vitamin A [diluted 1: 50;
Gibco]) and mammary epithelial growth medium aliquot of
gentamicin/amphotericin-B and recombinant human epidermal
growth factor (EGF), (SingleQuot) (Lorne Laboratories). Spheres
over 50 mM were counted and the percentage of cells plated which
formed spheres was calculated and is referred to as the percentage
mammosphere formation units (%MFU). All cells were main-
tained in a humidified incubator at 37uC at an atmospheric
pressure in 5% (v/v) carbon dioxide/air.
Wnt pathway inhibition. MCF10a, MCF7, MDA-MB-231,
primary human normal breast cells and primary human invasive
breast cancer cells were plated into MS culture and treated with a
single dose of human recombinant DKK1 (R and D systems) at
increasing concentrations (0–100ng/ml).
Wnt pathway activation. MCF10a, MCF7, MDA-MB-231,
Patient-derived normal and metastatic breast cancer cells were
plated into MS culture and treated with a single dose of mouse
Table 1. Primary metastatic breast cancer samples.
Sample ID Histology Source Grade ER PgR Her2
BB3RC30 IDC PE 2 Pos Pos UN
BB3RC33 ILC AS 2 Pos Pos Pos
BB3RC36 IDC PE 2 Pos Pos UN
BB3RC37 IDC PE UN Neg Neg Neg
BB3RC38 IDC AS 3 Neg Neg Neg
BB3RC39 IDC PE 3 Neg Neg Neg
Details of primary breast cancer samples used in this study. UN unknown, PE
pleural effusion, AS Ascites sample IDC invasive ductal carcinoma, ILC invasive
lobular carcinoma, ER oestrogen receptor alpha, PgR progesterone receptor,
Neg negative, Pos positive.
doi:10.1371/journal.pone.0067811.t001
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recombinant WNT3A (R and D systems) at increasing concen-
trations (0–50 ng/ml).
RNA Extraction and Real-time Quantitative PCR Assays of
Breast Cell Lines
Total RNA was extracted from the sixteen cell lines harvested at
log phase, using the RNeasyH Plus (Qiagen) kit following the
manufacturer’s protocol. For real-time quantitative PCR (qPCR),
mRNA was reverse-transcribed into cDNA using an ABI RT kit
(Applied Biosystems). qPCR primers and probes were designed
using Roche Probe Finder Design Software (Roche Applied
Sciences) and reactions performed using the ABI PRISM 7900
Sequence Detection System instrument and software (Applied
Biosystems). The reactions were incubated in a 384-well optical
plate at 95uC for 10 min, followed by 40 cycles of 95uC for 15 s
and 60uC for 10 min. Experiments were performed in triplicate
for each sample. Gene expression was normalized to internal
control SDHA (succinate dehydrogenase), YWHAZ (tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein,
zeta polypeptide).
RNA Extraction of Monolayer and AR Breast Cells
Cells were collected from 226L-U19, HB4a, MCF10a, MCF7,
T47D and SKBR3 cell lines cultured in monolayer (pre-incubated
with MS media for 12 hrs) and from viable AR cells. RNA was
extracted using the RNeasyH Plus Mini (Qiagen) following the
manufacturers protocol. In addition to the gDNA eliminator spin
column provided in the RNeasy kit, an on-column DNase
digestion was performed (RNase-Free DNase Set; Qiagen) to
ensure maximum removal of DNA. RNA was eluted and the
concentration measured using a GeneQuant machine (Amersham
Biosciences). RNA integrity was assessed by microanalysis (Agilent
Bioanalyser) and amplified using the WT-OvationTM Pico RNA
Amplification System (NuGEN) following the manufacturers
protocol which employs SPITM amplification (linear isothermal
DNA amplification process) to amplify the RNA about 15,000-
fold.
Custom Gene Expression Microarray Analysis of
Monolayer and AR Breast Cells
Custom microarray chips were designed using Agilent technol-
ogy. cDNA was fluorescently labelled using the FL-OvationTM
cDNA Fluorescent Module kit (NuGEN) with a single tag (CyTM3)
which incorporates into the cDNA. The fluorescently tagged
cDNA was loaded onto a microarray slides and the Agilent
microarray chips attached. Slides were incubated at 65uC for 40
hours in a hybridisation oven to allow hybridisation to occur. The
chips were then washed and scanned using an Agilent scanner.
Primary Breast Cancer Microarray
Affymetrix gene expression data representing a total of 1107
primary breast tumors from six previously published microarray
studies [23,24,25,26,27,28] were integrated as described previous-
ly using ComBat [29] to remove batch effects [30]. Centroid
prediction [31] was used to assign the tumors from each dataset to
the five Norway/Stanford subtypes (Basal, Luminal A, Luminal B,
ERBB2 and Normal-like [32].
Gene Expression Analysis
Centred average linkage clustering of cell lines, monolayer/
anoikis resistant cells and integrated tumour datasets was
performed using Cluster [33] and heatmaps generated using
TreeView programs as described previously [34].
Accession Numbers
Genbank accession numbers from NCBI, of genes used in
microarray are provided below. [Genbank: NM_004655,
NM_001904, NM_012242, NM_000125, NM_012193,
NM_003507, NM_003508, NM_002093, NM_030915,
NM_001130713, NM_002335, NM_002336, NM_003012,
NM_003013, NM_003014, NM_005985, NM_001083962,
NM_001204869, NM_003881, NM_005430, NM_025216,
NM_003394, NM_030761, NM_001256105, NM_030775].
Protein Analysis
Western blotting was carried out as previously described [35].
Antibodies used in this study were anti unphoshorylated B-catenin
(Upstate, Millipore) AXIN2 (Cell signalling) LEF1 (Cell signalling)
and DKK1 (abcam) and B-ACTIN (abcam).
Statistical Analyses
Normally distributed data was analysed using analysis of
variance (ANOVA) to determine significant differences of
DKK1 treatment followed by individual comparisons to control
(0 ng/ml) using the independent T-test. Data which deviated from
the normal distribution was analysed using Kruskall-wallis
followed by individual comparisons to control (0 ng/ml) using
the Mann Whitney U test. Gene expression: data was analysed using
two tailed students’t-tests.
Results
Activation of Wnt Signalling in Breast Cancer Cell Lines
Comprehensive analysis of WNT pathway mRNA expression
across a large panel of breast cell lines was performed, which
revealed cell type specific gene expression within the cell lines
tested (Figure 1A). Well established downstream targets, AXIN2
and LEF1 (Figure 1A) showed higher expression in breast cancer
cell lines suggesting activation of canonical WNT signalling.
Consistent with its gene expression level, LEF1 protein was higher
in five breast cancer cell lines compared to two normal cell lines
(MCF10A and 226LU19), providing further evidence that WNT
signalling is active in breast cancer cell lines (Figure 1B).
Interestingly, we observed high levels of LEF1 in the HER2
expressing cell line BT474. HER2 is known to activate b-catenin
activity which may account for this increase in the downstream
target LEF1 [36]. A WNT receptor and a WNT ligand were also
dysregulated in breast cancer cell lines, FZD4 showed higher
expression in breast cancer cell lines whilst WNT10A expression
was decreased. The expression pattern of WNT pathway genes
largely clustered the cell lines by estrogen receptor-a (ER) status;
ER+ve cell lines predominately expressed the downstream target
LEF1 whilst ER-ve cell lines express another downstream gene
AXIN2 (Figure 1A). As reported by others, WNT5A, LBH, WISP1
and TCF4 were expressed at lower levels in ER+ cell lines
compared to ER-ve cancer but also compared to immortalised
normal breast cell lines (Figure 1A), perhaps reflecting their ER-ve
status. Independent of ER status, overall WNT pathway signalling
assessed by the canonical downstream target genes AXIN2 and
LEF1 is higher in breast cancer cell lines compared to normal
breast cell lines.
Prognostic Value of WNT Expression in Breast Cancer
To assess the clinical importance of WNT pathway genes, we
performed analysis of a large cohort of breast cancer tumours
comprising six publically available gene expression data set [30].
Analysis of WNT signalling gene expression within defined
subtypes of breast cancer showed variation in gene expression
Wnt Pathway in Breast Cancer and Stem-Like Cells
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across the subgroups. Confirming the results observed using cell
lines (Figure 1) we observed higher expression of LEF1, suggesting
WNT activation in Luminal, ER+ve breast cancer patients
(Figure 2A). A number of genes were differentially expressed
between Luminal and Basal/ErbB2 breast cancer, such as
WNT5B, WNT10B and DKK1. A number of genes were highly
expressed specifically within the basal subtype of breast cancer,
LRP5, LRP6, and sFRP1 (Figure 2A). Analysis of these genes
showed significant associations to recurrence free survival within
breast cancer patients. The most significant association was with
sFRP1, where decreased expression predicts early recurrence in
ER+ve breast cancer, most likely due to lack of Wnt inhibition.
Lower levels of Lef1 were also predictive of recurrence in breast
cancer within the ER+ve subgroup. It might be expected that
higher levels of Lef1 would correlate with recurrence, however
lower Lef1 expression may identify a subgroup of ER+ve tumours
that have a basal-type phenotype, based upon their Wnt gene
expression. This subgroup within ER+ve tumours can also be
observed with analysis of Wnt5b, where high expression predicts
early recurrence, and where high expression is a marker of the
basal-type phenotype. LRP5 and LRP6 although demonstrating a
very similar expression profile within breast tumours have very
different effects on recurrence. Low expression of LRP6 in ER+ve
tumours was predictive of early recurrence, whilst low levels of
LRP5 was predictive of early recurrence in ER-ve breast cancer
(Figure 2B). LRP5/6 are co-receptors for WNT ligands, previously
thought to act similarly to activate downstream signalling. Recent
research suggests that they may actually function differently,
dependant upon physiological conditions and the type and
availability of WNT ligand [37,38]. Further investigations will
be needed to determine their precise roles in breast cancer.
Wnt Pathway Activation in Breast Cancer Stem-like Cells
Numerous reports implicate Wnt signalling in breast stem cell
activity [19,39,40]. To investigate this further, we employed the
mammosphere culture technique to enrich for cells with stem-like
activity, breast cancer stem-like cells (BCSCs). Anoikis resistant
(AR) cells are enriched for stem-like activity and have increased
tumour forming capacity in mice [15]. Comparison of MCF7 AR
cells to adherent monolayer cells showed an increase in active
WNT signalling in AR cells was confirmed by increased expression
of activated beta-catenin protein, both downstream targets
AXIN2, LEF1, and decreased expression of DKK1 protein
(Figure 3A and Figure S2).
Wnt Signalling is Suppressed in Normal Breast Stem-like
Cells
We next investigated WNT signalling gene expression using a
custom Agilent microarray using AR-derived and monolayer
cultured populations from 3 immortalised normal and three breast
cancer cell lines. AR-derived populations contain stem-like cells,
which has been validated by in vivo tumour initiation [15;Ablett
et al submitted]. Gene expression analysis confirmed results in
Figure 1 that there are higher levels of WNT signalling in breast
cancer cell lines compared to normal breast cell lines when grown
in either monolayer or AR culture (Figure S1). Fold change
differences between monolayer and AR cells (enriched for BCSCs)
for each cell line were calculated and displayed as a heatmap
(Figure 3B). Importantly, analysis of the change in gene expression
between monolayer cultured and AR cells (enriched for BCSCs)
showed differences between breast cancer and normal cell lines
(Figure 3B). WNT ligands WNT1, WNT10a and WNT4 were
expressed at higher levels in normal AR cells compared to
monolayer cells, however in the breast cancer cell lines, their
expression was lower in the AR cells compared to monolayer cells.
sFRP1 and b-catenin were highly expressed in BCSCs from ER+ve
breast cancer cell lines (MCF7 and T47D). No increase in
expression was observed in the ER-ve breast cancer cell line tested
(SK3RB) suggesting that canonical WNT signalling in BCSCs may
correlate with ER (Figure 3B). Most importantly, we found higher
levels of the WNT signalling gene LEF1 in BCSCs compared to
monolayer cells, irrespective of ER expression, while normal
breast stem cell populations showed lower levels compared to
normal monolayer cells (Figure 3B). The data demonstrates
specific upregulation of WNT pathway signalling in a population
enriched for BCSCs.
Modulation of Wnt Pathway Signalling Affects Stem Cell-
like Activity
To test the potential of targeting the WNT pathway we
investigated the effects of WNT pathway modulation in cell lines.
Cells were cultured as mammospheres (MS) with increasing
concentrations of either DKK1 to inhibit or WNT3A to activate
the WNT pathway. Recombinant WNT3A treatment significantly
increased the number of MS in both normal (MCF10A) and breast
cancer (MCF7 and MDA-MB-231) cell lines (Figure 4A–C).
DKK1 treatment significantly decreased the number of MS in all
cell lines tested with the most significant decrease observed using
the highest concentration (100 ng/ml) of DKK1 (Figure 4D–F).
Using patient-derived cell samples from both ER+ve (n = 3) and
ER-ve (n = 3) breast cancer and normal breast tissue (n = 3) we
found that WNT3A caused a significant increase in MS only in the
ER-ve sample (Figure 5C). Inhibition of WNT signalling using
DDK1 showed that low dose (5 ng/ml) treatment was sufficient to
decrease mammosphere formation in primary breast cancer cells
whilst leaving the normal cells of the breast unaffected. Only high
concentrations (100 ng/ml) of DKK1 were sufficient to inhibit MS
formation in normal primary breast cells (Figure 5D–F).
Discussion
Our results are consistent with existing data [16,41] which
suggest activation of WNT signalling in breast cancer through the
increased expression of key signalling components and down-
stream target such as LEF1 at both the mRNA and protein level.
We observed higher levels of WNT signalling in breast cancer cell
lines correlating with ER expression. Although both classical
downstream targets AXIN2 and LEF1 were on average expressed
at higher levels in breast cancer cell lines, ER-ve cell lines
expressed the highest levels of AXIN2 whereas the major
downstream target activated in ER+ve cell lines was LEF1
demonstrating the subtle differences in WNT signalling that can
occur.
Figure 1. Wnt signalling in normal breast cell lines (N), ER-ve (T2) and ER+ve (T+) breast cancer cell lines. A) mRNA expression was
normalised to house keeper genes. Cluster analysis was performed and data displayed in a heatmap: decreased (green) or increased (red) expression
compared to the mean mRNA expression. (Red)qq Indicates significant increased expression (,0.05) (red)q indicates a trend towards increased
expression. (Green) QQ Indicates significant increased expression (,0.05) (green) Q indicated a trend towards increased expression. B) Protein
expression of Lef 1 and B-actin (housekeeper) in normal breast cell lines (N), ER-ve (T2) and ER+ve (T+) breast cancer cell lines.
doi:10.1371/journal.pone.0067811.g001
Wnt Pathway in Breast Cancer and Stem-Like Cells
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Figure 2. Analysis of mRNA expression in primary human breast cancer samples. Expression data was combined from multiple studies into
a combined cohort of ERBB2 (n = 194) Basal (172) Luminal A (n = 336) and Luminal B (161) and normal-like (n = 244) subtypes of breast cancer. A)
mRNA expression data was displayed in a heatmap: decreased (green) or increased (red) expression compared to the mean mRNA expression. % of
samples with high gene expression are detailed and denoted as green when expression is decreased and red when expression is increased. B) Kaplan
Meier plots Wnt gene expression show the years of recurrence free survival, where red indicates lower gene expression and blue indicates higher
gene expression. * Red #upper quartile: Blue .upper quartile ** Red #lower quartile: Blue .lower quartile. P values were generated and significant
results were highlighted in red.
doi:10.1371/journal.pone.0067811.g002
Wnt Pathway in Breast Cancer and Stem-Like Cells
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We also observed a lack of expression of a subset of genes
including WNT5A mRNA in ER+ve breast cancer cell lines.
Recent studies suggest that WNT5A plays a critical role in
malignant progression although loss of WNT5A protein has been
linked with poor prognosis in breast cancer and correlated with the
loss of ER expression [42]. This is contradictory to our
observations of higher WNT5A mRNA expression in ER-ve cell
lines but reported data suggests an inverse relationship between
mRNA levels and expression of WNT5A protein [43,44,45].
Other genes that were inversely correlated with ER expression
included LBH, WISP1, and TCF4. LBH is a newly identified target
of the WNT/b-CATENIN signalling pathway expressed at
abnormally high levels in poorly differentiated, basal-subtype,
ER-ve [46]. WISP1 is overexpressed in breast cancer and was
associated with advanced clinical features [47]. TCF4 has been
reported to interact with ER signalling [48].
We next examined Wnt pathway gene expression in 1107
primary breast cancer tumours and found differences across
subtypes of breast cancer. Many were associated with both basal
and ERBB2 sub-types such as WNT5B and others specifically in
basal cancers such as LRP5/6 and sFRP1. Lower levels of sFRP1 or
LRP6 predict an early recurrence in ER+ve breast cancer whilst
higher levels of WNT5B expression predict early recurrence. LRP5
was the only gene that was predictive in ER-ve breast cancer
where low levels predict early recurrence. The downstream target
LEF1, which was upregulated in ER+ve cell lines, was also
increased in Luminal sub-type patient samples and lower levels
predicted recurrence in ER+ve patients. These analyses demon-
strate the importance of Wnt signalling in breast cancer, and
highlight a subgroup of ER+ve patients with a basal-type
phenotype based upon their Wnt expression and decreased
recurrence free survival.
Our data has shown that the WNT pathway activation is
significantly higher in populations enriched for BCSCs, while
populations enriched for normal stem-like cells have lower levels of
WNT signalling. Furthermore, our data suggests that normal
breast cancer stem cells express different WNT ligands (WNT4
and WNT10) than BCSCs when compared to their monolayer
populations. Little is known about the role of WNT10A in breast
cancer but Wnt4 is essential for normal progesterone induced
mammary gland development [49]. A subset of genes such as
sFRP1 and b-CATENIN, despite being lower in ER+ compared to
ER-ve cell lines, was higher in BCSCs of ER+ve cells. This
suggests that BCSCs from ER+ve cell lines share a similar
expression profile to cells from an ER2ve cell line supporting the
growing hypothesis of a cell hierarchy in which stem cells in
ER+ve tumours are ER-ve [50]. Finally we established that the
WNT pathway regulates MS formation. WNT3A treatment
caused a significant increase in MS in the MCF7 and MDA-
MB-231 cancer cell lines while MCF10a immortalised normal
breast cells were less sensitive.
To demonstrate biologically the clinical relevance of WNT
modulation, we used patient-derived breast samples from both
normal and cancerous tissue and compared them to cell lines.
Patient-derived samples responded less sensitively to WNT
modulation and only ER2ve patient-derived breast cancer cells
Figure 3. Gene expression analysis of Wnt signalling in
monolayer (Mono) and anoikis resistant (AR) cells of normal
breast cell lines (N), ER-ve and ER+ve breast cancer cell lines. A)
Protein expression of activated B-catenin (unphosphorylated), Lef1,
Axin2, DKK1 and B-actin (housekeeper) in MCF7 monolayer and AR cells.
B) Cluster analysis was performed using the fold change in expression
between Mono and AR cells. Data is displayed in a heatmap
represented by either decreased (green) or increased (red) expression
compared to the mean mRNA expression. (Red) qq Indicates
significant increased expression (,0.05) (red) q indicates a trend
towards increased expression. (Green) QQ Indicates significant
increased expression (,0.05) (green) Q indicated a trend towards
increased expression.
doi:10.1371/journal.pone.0067811.g003
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responded to WNT activation. Treatment with the WNT inhibitor
DKK1 successfully decreased MS in both ER+ve and ER-ve
patient-derived samples with most significant reduction in ER+ve
cells. The data suggest that moderate DKK1 concentrations were
sufficient to inhibit MS and therefore stem cell-like activity in both
ER+ve and ER2ve tumours whilst not affecting the activity within
normal breast tissue. This agrees with the recent in vivo studies of
Gurney et al (2012), who show that a therapeutic antibody to the
FZD receptor can prevent cancer stem cell activity without toxicity
in normal stem cells [51].
Conclusions
In conclusion, we indentified a number of novel WNT signalling
components in BCSC signalling. LEF1 has shown the most
consistent activation in breast cancer cell lines and increased
expression in BCSCs in both ER2ve and ER+ve patient breast
cancer samples. Finally, we show that WNT pathway inhibition
Figure 4. Modulation of Wnt signalling in normal and breast cancer cell lines. Single cells were plated in non-adherent conditions and
treated with increasing concentrations of either Wnt3a (0–50 ng/ml) or DKK1 (0–100 ng/ml) and cultured for 7 days and number of mammospheres
counted. Wnt3a treatments are displayed in the left panel and DKK1 treatments in the right panel. Light grey bars represent untreated control A)
MCF10a cells (Wnt3a) B) MCF7 cells (Wnt3a) C) MDA-MB-231 cells (Wnt3a) D) MCF10a cells (DKK1) E) MCF7 cells (DKK1) F) MDA-MB-231 cells (DKK1).
Data is expressed as % mammosphere formation units. P values were generated by ANOVA. Asterisks mark individual comparisons which reached
statistical significance * ,0.01 ** ,0.001 generated by a T-test. G) Image of a MCF10a mammosphere H) Image of an MCF7 mammosphere I) Image
of an MDA-MB-231 mammosphere. Scale bar represents 50 mM.
doi:10.1371/journal.pone.0067811.g004
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preferentially reduces stem-like cell activity in patient-derived
metastatic breast cancer compared to normal cells. Collectively,
these data suggest potential of the WNT-targeted therapeutics in
breast cancer.
Supporting Information
Figure S1 Gene expression analysis of Wnt signalling in
monolayer (MO) and anoikis resistant (AR) cells of normal breast
cell lines (N), ER positive (ER+) and ER negative (ER2) breast
cancer cell lines. B) Cluster analysis was performed using gene
expression data of cells in MO and AR. Data is displayed in a
heatmap represented by either decreased (green) or increased (red)
expression compared to the mean mRNA expression. (Red) qq
Indicates significant increased expression (,0.05), (red) q
indicates a trend towards increased expression. (Green) QQ
Indicates significant increased expression (,0.05), (green) Q
indicated a trend towards increased expression.
(TIF)
Figure S2 Full membranes used to detect Wnt signalling protein
expression. Protein was quantified and gel loading volumes
Figure 5. Modulation of Wnt signalling in normal and primary breast cancer samples (Normal n=3; ER+ve n=3; ER-ve n=3). Single
cells were plated in non-adherent conditions and treated with increasing concentrations of either Wnt3a (0–50 ng/ml) or DKK1 (0–100 ng/ml) and
cultured for 7 days and number of mammospheres counted. Wnt3a treatments are displayed in the left panel and DKK1 treatments in the right panel.
Light grey bars represent untreated control A) primary normal breast cells (Wnt3a) B) ER+ve primary breast cancer cells (Wnt3a) C) ER-ve primary
breast cancer cells (Wnt3a) D) primary normal breast cells (DKK1) E) ER+ve primary breast cancer cells (DKK1) F) ER2ve primary breast cancer cells
(DKK1). Data is expressed as % mammosphere formation units. P values were generated by ANOVA. Asterisks mark individual comparisons which
reached statistical significance * .0.01 ** .0.001 generated by a T-test. G) Image of a normal primary mammosphere H) Image of an ER positive
primary tumour mammosphere I) Image of an ER negative primary tumour mammosphere. Scale bar represents 50 mM.
doi:10.1371/journal.pone.0067811.g005
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determined to achieve equal loading of 50 ug. Multiple gels were
loaded concurrently with protein and probed for activated B-
catenin (unphosphorylated), Lef1, Axin2, DKK1 and B-actin
(housekeeper) in MCF7 monolayer (Day1 mono) and AR cells
(Day 1 MS). B-actin was probed using Gel 1. * marks the band
that represents the protein of interest.
(TIF)
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